NDA 208552 · Mayne Pharma
Rhofade
Oxymetazoline Hydrochloride · Topical
NovelLast checked: Nov 19, 2026Latest source record: Jan 18, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Jan 18, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
655
76 Phase 3, 27 recruiting
FAERS reports
910
410 serious, 26 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 13, 2026.
Oxymetazoline Hydrochloride Cream, 1% is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. Oxymetazoline Hydrochloride Cream is an alpha 1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. ( 1 )
Mechanism: Oxymetazoline is an alpha 1A adrenoceptor agonist. Oxymetazoline acts as a vasoconstrictor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 18, 2017 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated NovelLetterLabelReview
1 products under this application
- RHOFADE · OXYMETAZOLINE HYDROCHLORIDE 1% · CREAM, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxymetazoline" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac SurgeryPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06802224 · 18,000 participants (planned) · Start Apr 1, 2025 · Primary completion Jul 2028
Drug: Norepinephrine; Phenylephrine · For: Anesthesia; Surgery With General Anesthesia; Noncardiac Surgery and 4 more
Sites: San Francisco, California; College Park, Maryland; Ann Arbor, Michigan · 10 sites in all
- The GUARDIAN Trial - Vasopressor Sub-StudyPivotal-lookingEnrolling by invitation
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT04934748 · 6,254 participants (planned) · Start Jul 25, 2021 · Primary completion Dec 31, 2026
Drug: Phenylephrine; Norepinephrine · For: Blood Pressure
Sites: Omaha, Nebraska; Cleveland, Ohio; Beijing, China · 11 sites in all
- Norepinephrine vs Phenylephrine During General AnesthesiaPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04789330 · 3,626 participants · Start Jul 1, 2021 · Primary completion Apr 1, 2022
Drug: Norepinephrine; Phenylephrine · For: Anesthesia; Surgery; Hypotension
Sites: Los Angeles, California; San Francisco, California · 5 sites in all
- Target Hemodynamics and Brain Injury During General Anesthesia in the ElderlyPivotal-lookingSuspended
Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoAcademic, hospital or other
NCT02428062 · 1,812 participants (planned) · Start Oct 2014 · Primary completion Dec 2018
Drug: Phenylephrine; Intravenous fluids and 4 more · For: Post-operative Cognitive Dysfunction
Sites: Milan, Italy
- OB VEGA-Phenylephrine vs Norepinephrine OutcomesPivotal-lookingNot yet recruiting
Wake Forest University Health SciencesAcademic, hospital or other
NCT07900919 · 1,500 participants (planned) · Start Jan 2027 · Primary completion Dec 2027
Drug: Phenylephrine; Norepinephrine · For: Hypotension During Surgery; Cesarean Birth
Sites: Winston-Salem, North Carolina
- Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac SurgeryPivotal-lookingRecruiting
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT05635227 · 1,200 participants (planned) · Start Nov 10, 2022 · Primary completion Dec 2027
Drug: Dexamethasone phosphate; Isotonic sodium chloride (0.9%) and 2 more · For: Coronary Artery Disease; Aortic Valve Disease
Sites: Copenhagen, Denmark
- Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-GrowthPivotal-lookingNot yet recruiting
Applied Biology, Inc.Industry
NCT06648850 · 1,120 participants (planned) · Start May 1, 2026 · Primary completion Mar 19, 2027
Drug: DA-001; Phenylephrine and 1 more · For: Telogen Effluvium; Female Pattern Hair Loss; Female Pattern Hair Loss, Androgenic Alopecia and 3 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- application site erythema84
- drug ineffective64
- nausea55
- rosacea54
- fatigue53
- application site pain49
- erythema48
- pain47
- pruritus45
- diarrhoea44
- condition aggravated39
- headache39
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 6 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 7 |
| 2013 | 11 |
| 2014 | 9 |
| 2015 | 11 |
| 2016 | 23 |
| 2017 | 53 |
| 2018 | 85 |
| 2019 | 79 |
| 2020 | 41 |
| 2021 | 58 |
| 2022 | 122 |
| 2023 | 132 |
| 2024 | 91 |
| 2025 | 106 |
| 2026 | 59 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rhofade (Oxymetazoline HCl)
2024 spending
$928K
Beneficiaries
1,269
1,474 claims
Per beneficiary
$731
$19.99 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $1,748,180 |
| 2022 | $2,655,700 |
| 2023 | $2,516,617 |
| 2024 | $927,789 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Post-acne erythema treatment: A systematic review of the literature.
Kalantari Y, Dadkhahfar S, Etesami I · J Cosmet Dermatol 2022 · Systematic Review
- Common cold.
Arroll B · BMJ Clin Evid 2008 · Systematic Review
- Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis.
Gao X, Xiang W · Actas Dermosifiliogr 2025 · Systematic Review, Meta-Analysis
- Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.
van Zuuren EJ, Fedorowicz Z, Tan J, et al. · Br J Dermatol 2019 · Systematic Review
- Laser and energy-based devices for treating rosacea - a systematic review and network meta-analysis.
Nguyen L, Sorbe C, Seeber N, et al. · J Dtsch Dermatol Ges 2026 · Network Meta-Analysis, Systematic Review
- Olfactory function in acute rhinitis.
Hummel T, Rothbauer C, Barz S, et al. · Ann N Y Acad Sci 1998 · Clinical Trial, Randomized Controlled Trial
Sponsor: Mayne Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.